Natasja Brooijmans, Ph.D.
Dr. Brooijmans joined Scorpion Therapeutics in June 2020 and currently serves as Senior Vice President leading the Chemical Data Science team, which includes computational chemists, computational biophysicists, and machine learning…
Dr. Brooijmans joined Scorpion Therapeutics in June 2020 and currently serves as Senior Vice President leading the Chemical Data Science team, which includes computational chemists, computational biophysicists, and machine learning specialists. She also leads Scorpion’s Protein and Structural Sciences team.
Prior to joining Scorpion Therapeutics, Dr. Brooijmans was part of the founding scientific team at Blueprint Medicines, where she helped build the scientific software infrastructure, the strategy and design of the Blueprint Library, and contributed to most of the drug discovery programs in Blueprint’s pipeline, including FGFR4, RET, ALK2, EGFR, and MAP4K1. Prior to Blueprint, she worked at Novartis supporting early-stage programs using data analytics and structure-based approaches. She started her career at Wyeth, where she contributed to kinase drug discovery programs and developed a kinase knowledge-based software application.
Dr. Brooijmans received her Ph.D. from the University of California, San Francisco in Chemistry and Chemical Biology, and received her M. Pharm. from Utrecht University.